Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 211

Sort by

Sort Order Select

Journal Articles

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Jennifer A. Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Árpád Illés, Arnon P. Kater, Paolo Ghia, John C. Byrd, John F. Seymour, Susan Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla

Blood (2024) 144 (10): 1061–1068.

https://doi.org/10.1182/blood.2023023659

Published: 2024

Includes: Supplemental data

Journal Articles

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Blood (2024) 144 (8): 867–872.

https://doi.org/10.1182/blood.2023023388

Published: 2024

Includes: Supplemental data

Journal Articles

Degraders upgraded: the rise of PROTACs in hematological malignancies

Joshua M. L. Casan, John F. Seymour

Blood (2024) 143 (13): 1218–1230.

https://doi.org/10.1182/blood.2023022993

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Blood (2024) 143 (8): 673–684.

https://doi.org/10.1182/blood.2023021306

Published: 2024

Includes: Supplemental data

Journal Articles

Risk/benefit of BTK/venetoclax combos: the context matters!

John F. Seymour

Blood (2024) 143 (7): 563–564.

https://doi.org/10.1182/blood.2023022896

Published: 2024

Journal Articles

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Blood (2023) 142 (23): 1960–1971.

https://doi.org/10.1182/blood.2023020301

Published: 2023

Includes: Supplemental data

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 981.

https://doi.org/10.1182/blood-2023-181627

Published: 2023

Journal Articles

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 1737.

https://doi.org/10.1182/blood-2023-181108

Published: 2023

Journal Articles

Obinutuzumab, Lenalidomide and Venetoclax in Patients with Treatment-Naïve Advanced-Stage Follicular Lymphoma: First Results of the Investigator-Initiated Phase Ib/II, Multicenter Leverage Study

Chan Y. Cheah, Katharine L. Lewis, Rory Bennett, Amanda Jane Johnston, Joel Wight, Jing Xie, Stella Vlahos, Katrina Celeste, Sally Binks, John F. Seymour

Blood (2023) 142 (Supplement 1): 1659.

https://doi.org/10.1182/blood-2023-184660

Published: 2023

Journal Articles

Analysis of Ventricular Arrhythmias and Sudden Death with Acalabrutinib from 5 Prospective Clinical Trials

Jeff P. Sharman, Paolo Ghia, Paulo Andre P. Palhares De Miranda, Naghmana Bajwa, Simon Rule, Bob Shaw, John F. Seymour

Blood (2023) 142 (Supplement 1): 4643.

https://doi.org/10.1182/blood-2023-174913

Published: 2023

Journal Articles

Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

Rosemary Anne Harrup, Arnon P. Kater, Barbara F. Eichhorst, Carolyn Owen, Brenda Chyla, Hyun Yong Jin, Yanwen Jiang, Yi Meng Chang, Rosemary Millen, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, John F. Seymour

Blood (2023) 142 (Supplement 1): 1898.

https://doi.org/10.1182/blood-2023-177567

Published: 2023

Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Blood (2023) 142 (Supplement 1): 325.

https://doi.org/10.1182/blood-2023-185852

Published: 2023

Journal Articles

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

John F. Seymour, Chan Yoon Cheah, Ricardo Parrondo, Meghan C. Thompson, Don A. Stevens, Masa Lasica, Michael L. Wang, Abhijeet Kumar, Judith Trotman, Maan Alwan, Wei Ding, Kunthel By, Bilal Tariq, Xiangmei Chen, Shannon Fabre, Jason Paik, Amit Agarwal, Constantine S. Tam

Blood (2023) 142 (Supplement 1): 4401.

https://doi.org/10.1182/blood-2023-180109

Published: 2023

Journal Articles

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Ing Soo Tiong, Tamia Nguyen, Charis Teh, Chong Chyn Chua, Sarah Ftouni, Thomas E Lew, Fiona C. Brown, Donia Moujalled, Christine Muttiah, Daniel Gray, Mary Ann Anderson, Philip A. Thompson, Constantine S. Tam, John F. Seymour, Sarah-Jane Dawson, Andrew H. Wei, Geoffrey Lindeman, Piers Blombery

Blood (2023) 142 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2023-180386

Published: 2023

Journal Articles

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

Blood (2023) 142 (Supplement 1): 6535.

https://doi.org/10.1182/blood-2023-186145

Published: 2023

Journal Articles

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2 ) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

Lorenzo Falchi, Franck Morschhauser, Kim Linton, Huiqiang Huang, Faith Galderisi, Syed Quadri, Lingmin Zeng, Daniela Hoehn, John F. Seymour

Blood (2023) 142 (Supplement 1): 3053.

https://doi.org/10.1182/blood-2023-180092

Published: 2023

Journal Articles

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach

Blood (2023) 142 (8): 687–699.

https://doi.org/10.1182/blood.2022018818

Published: 2023

Includes: Supplemental data

Journal Articles

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Blood (2022) 140 (20): 2127–2141.

https://doi.org/10.1182/blood.2022016040

Published: 2022

Includes: Supplemental data

Journal Articles

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, John C. Byrd, Talha Munir, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Jennifer R. Brown, Anthony R. Mato, Stephan Stilgenbauer, Thomas Fehn, Paulo Andre P. de Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach

Blood (2022) 140 (Supplement 1): 7050–7052.

https://doi.org/10.1182/blood-2022-157060

Published: 2022

Journal Articles

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

Adrian Minson, Nada Hamad, Chan Y. Cheah, Constantine S. Tam, Piers Blombery, David A Westerman, Stephen Lade, David Ritchie, Rachel M Koldej, Mary Ann Anderson, Amit Khot, John F. Seymour, Molly Robertson, Imogen R Caldwell, Georgina L Ryland, Jing Xie, Huw Morgan, Michael Dickinson

Blood (2022) 140 (Supplement 1): 181–183.

https://doi.org/10.1182/blood-2022-160459

Published: 2022

NARROW

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Degraders upgraded: the rise of PROTACs in hematological malignancies

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Risk/benefit of BTK/venetoclax combos: the context matters!

Sorafenib plus intensive chemotherapy in newly diagnosed FLT3 -ITD AML: a randomized, placebo-controlled study by the ALLG

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients with Prior cBTKi: Safety and Efficacy Including High-Risk Subgroup Analyses from the Phase 1/2 BRUIN Study

Pirtobrutinib in Richter Transformation: Updated Efficacy and Safety Results with 18-Month Median Survival Follow-up from the Phase 1/2 BRUIN Study

Obinutuzumab, Lenalidomide and Venetoclax in Patients with Treatment-Naïve Advanced-Stage Follicular Lymphoma: First Results of the Investigator-Initiated Phase Ib/II, Multicenter Leverage Study

Analysis of Ventricular Arrhythmias and Sudden Death with Acalabrutinib from 5 Prospective Clinical Trials

Response to Subsequent Novel Therapies and Time to Second Progression-Free Survival Event in the MURANO Trial in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with Fixed-Dose Venetoclax Plus Rituximab

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

First Results from a Phase 1, First-in-Human Study of the Bruton's Tyrosine Kinase (BTK) Degrader Bgb-16673 in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Malignancies (BGB-16673-101)

BAX Mutated Clonal Hematopoiesis Arises Following Treatment with the BCL2 Inhibitor Class of Therapeutics across a Range of Hematological and Non-Hematological Neoplasms

Patient-Reported Outcomes (PROs) Among Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Receiving Pirtobrutinib: Analysis from the BRUIN Phase 1/2 Study

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2 ) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only